Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | AGTR2 | P50052 | 10/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6017192 | 0.91 | TSHR (0.52) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL6515997 | 0.87 | AGTR2 (0.56) | AGTR2BDKRB2POLB | |
| SCHEMBL15241314 | 0.87 | AGTR2 (0.56) | AGTR2BDKRB2POLB | |
| SCHEMBL29921 | 0.87 | AGTR2 (0.56) | AGTR2BDKRB2POLB | |
| SCHEMBL6281354 | 0.87 | AGTR2 (0.56) | AGTR2BDKRB2POLB | |
| SCHEMBL6936885 | 0.86 | AGTR2 (0.46) | AGTR2POLB | |
| SCHEMBL12849519 | 0.86 | AGTR2 (0.46) | AGTR2POLB | |
| SCHEMBL23532545 | 0.86 | TSHR (0.50) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL4725266 | 0.84 | CYP19A1 (0.45) | ALDH1A1ECE1 | |
| SCHEMBL30580462 | 0.84 | TSHR (0.48) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9382258-B2 | Agents for treating pain and uses thereof | ABBVIE INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150225409-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ABBVIE INC. | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225409-A1 | AGENTS FOR TREATING PAIN AND USES THEREOF | ACHE, MPO, CALCA | TSHR 4461/4885TDP1 2600/4885L3MBTL1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.